Funder: Children's Cancer Research Fund
Due Dates: August 7, 2026 (LOI) | November 16, 2026 (Full application)
Funding Amounts: Up to $1,000,000 in total costs over a maximum of 36 months
Summary: Supports clinical trials for hard-to-treat childhood cancers, prioritizing Phase 0–Phase 2 studies.
Key Information: CCRF accepts only one letter of intent per Principal Investigator per calendar year across its grant programs.
Description
Children's Cancer Research Fund (CCRF) supports clinical trials seeking better treatments for hard-to-treat childhood cancers through the Accelerating Hope award. The program prioritizes Phase 0–Phase 2 trials and is limited to clinical research. It advances CCRF’s commitment to safer, less toxic therapies for children with cancer.
For this award, “hard-to-treat” means five-year survival below 70% for an individual childhood cancer, a cancer with unfavorable behavior such as relapse or metastasis, or a molecularly defined subtype. Examples include osteosarcoma, AML, DIPG, MLL-rearranged leukemia, and PAX3-FOXO1-rearranged RMS. Cancers with survival below 70% in groups defined by age, sex, or race/ethnicity may also qualify when pursuing a biologic hypothesis. Applicants must substantiate fit with this definition using scientific literature.
